Mayne Pharma Group (ASX:MYX) reports one of its US-based subsidiary companies has executed a licence and supply agreement with pure-play dermatology category leader Galderma.
The company says the agreement has been signed for an unbranded authorised generic version of ORACEA 40mg capsules being manufactured pursuant to NDA 050805 and indicated for the treatment of only inflammatory lesions of rosacea in adult patients.
Mayne Pharma Group notes the agreement grants the company an exclusive 3-year licence of the authorised generic for the US market, and also aligns with its mission of expanding access to ‘high quality’ medicines.
“Our goal, as always, is to ensure widespread access, reducing the burden on prescriber and patient ability to get high quality dermatology medications”
The company also notes the agreement builds on core strengths and broadens its portfolio of dermatology products.
Speaking on the agreement, Mayne Pharma Chief Executive Officer (CEO) Shawn O’Brien said: “This agreement provides another example of how we are building on our core strengths and expanding our portfolio of dermatology products.
We continue to focus on identifying and taking advantage of strategic expansion opportunities, and generic ORACEA fits well within our roster of products to help patients have healthier skin. Our goal, as always, is to ensure widespread access, reducing the burden on prescriber and patient ability to get high quality dermatology medications. This will allow us to drive revenue growth and deliver value to shareholders.”
In addition, it is reported the ORACEA market was valued at about US$210 million for CY22 according to leading healthcare data and analytics provider IQVIA.
Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising novel and generic pharmaceuticals, offering patients better, safe, and more accessible medicines. The company also provides contract development and manufacturing services to clients worldwide, with a 40-year track record of innovation and success in developing new oral drug delivery systems.
